Biogen Inc.
250.69USD
-3.1500 (-1.24%)
Not enough data yet
A reading needs 5 members, each at least 14 days old with a track record on this site (simulated portfolios and calls), who shared a take in the last 30 days; 2 of them need a strong record.
Sign in to share your take on BIIB.
Consensus EPS on the street’s adjusted basis, not the filed GAAP figure — which is why the actuals here can differ from the income statement.
| Period | Consensus EPS | 90 days ago | Revisions up (30d) | Revisions down (30d) |
|---|---|---|---|---|
| Current quarter | $1.97▼ | $2.48 | 2 | 2 |
| Next quarter | $3.28▼ | $3.55 | 3 | 1 |
| Current year | $12.36▲ | $11.98 | 2 | 3 |
| Next year | $16.44▲ | $16.42 | 2 | 1 |
Beat in 4 of the last 4
| Quarter | Estimate | Actual | Surprise |
|---|---|---|---|
| 2026-06-30 | $2.03 | $3.6 | +1.57 (+77.4%) |
| 2026-03-31 | $2.95 | $3.57 | +0.62 (+20.9%) |
| 2025-12-31 | $1.62 | $1.99 | +0.37 (+23.2%) |
| 2025-09-30 | $3.88 | $4.81 | +0.93 (+23.9%) |
646 ratings from 46 firms
Ratings are attributed to the research firm, not to individual analysts. See every ticker.
| Firm | Action | Rating | Price Target | Date |
|---|---|---|---|---|
| B of A Securities | Maintained | Neutral | $219 $244 | Oct 22, 2026 |
| TD Cowen | Maintained | Buy | $225 $250 | Oct 21, 2026 |
| Wells Fargo | Maintained | Overweight | $250 $310 | Oct 20, 2026 |
| JP Morgan | Upgraded from Neutral | Overweight | $210 $300 | Oct 12, 2026 |
| UBS | Maintained | Buy | $240 $270 | Oct 9, 2026 |
| RBC Capital | Maintained | Outperform | $260 $256 | Oct 8, 2026 |
| HSBC | Maintained | Reduce | $165 $175 | Sep 10, 2026 |
| Piper Sandler | Reiterated | Overweight | $225 $245 | Sep 3, 2026 |
| RBC Capital | Maintained | Outperform | $240 $260 | Aug 25, 2026 |
| Wolfe Research | Upgraded from Peer Perform | Outperform | $300 | Aug 13, 2026 |
| Mizuho | Maintained | Outperform | $221 $241 | Aug 4, 2026 |
| Citigroup | Maintained | Neutral | $200 $215 | Aug 3, 2026 |
| UBS | Maintained | Buy | $225 $240 | Jul 30, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $237 $251 | Jul 30, 2026 |
| Morgan Stanley | Maintained | Equal-Weight | $222 $231 | Jul 30, 2026 |
| RBC Capital | Maintained | Outperform | $242 $240 | Jul 30, 2026 |
| Canaccord Genuity | Maintained | Buy | $245 $248 | Jul 30, 2026 |
| TD Cowen | Maintained | Buy | $215 $225 | Jul 30, 2026 |
| Wedbush | Maintained | Neutral | $201 $215 | Jul 30, 2026 |
| Barclays | Maintained | Equal-Weight | $185 $200 | Jul 29, 2026 |
| Guggenheim | Maintained | Buy | $260 $280 | Jul 21, 2026 |
| B of A Securities | Maintained | Neutral | $217 $215 | Jul 21, 2026 |
| Truist Securities | Upgraded from Hold | Buy | $190 $235 | Jul 13, 2026 |
| Morgan Stanley | Maintained | Equal-Weight | $224 $222 | Jul 8, 2026 |
| RBC Capital | Maintained | Outperform | $227 $242 | Jul 7, 2026 |
76 filings from 23 insiders · 12 buy / 1 sell over 6m
Officers and directors of BIIB, from the last two years of filings. Grants, gifts and option exercises are shown but not colour-coded — they are compensation, not a view on the price.
| Insider | Action | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Godbout SeanOfficer, Chief Accounting Officer | ExerciseRestricted Stock Unit | 27 | — | — | Oct 2, 2026 |
| Godbout SeanOfficer, Chief Accounting Officer | Tax | 8 | $219.88 | $2k | Oct 2, 2026 |
| Godbout SeanOfficer, Chief Accounting Officer | Exercise | 27 | — | — | Oct 2, 2026 |
| Godbout SeanOfficer, Chief Accounting Officer | GrantRestricted Stock Unit | 985 | — | — | Oct 1, 2026 |
| Parini MichaelOfficer, Chief Legal Officer | GrantRestricted Stock Unit | 7.4k | — | — | Sep 1, 2026 |
| MINOR LLOYD B.Director | Sell | 1.2k | $200.96 | $240k | Aug 4, 2026 |
| PANGALOS MENELAS NDirector | Other | 2.4k | — | — | Jun 9, 2026 |
| ROWINSKY ERIC K.Director | Grant | 1.5k | — | — | Jun 9, 2026 |
| HAWKINS WILLIAM A IIIDirector | Grant | 1.5k | — | — | Jun 9, 2026 |
| SHERWIN STEPHEN ADirector | Grant | 1.5k | — | — | Jun 9, 2026 |
| FREIRE MARIA CDirector | Grant | 2.0k | — | — | Jun 9, 2026 |
| MANTAS JESUS BDirector | Grant | 1.5k | — | — | Jun 9, 2026 |
| PATOLAWALA MONISH DDirector | Grant | 1.5k | — | — | Jun 9, 2026 |
| LANGER SUSANDirector | Grant | 1.5k | — | — | Jun 9, 2026 |
| PANGALOS MENELAS NDirector | Grant | 1.5k | — | — | Jun 9, 2026 |
| MINOR LLOYD B.Director | Grant | 1.5k | — | — | Jun 9, 2026 |
| KEENEY ADAM JAMESOfficer | Other | 939 | — | — | May 1, 2026 |
| GODBOUT SEANOfficer | Other | 181 | — | — | Apr 1, 2026 |
| MURPHY NICOLEOfficer | Buy | 3 | $195.04 | $585 | Feb 12, 2026 |
| SINGHAL PRIYAOfficer | Sell | 2.7k | $199.83 | $532k | Feb 9, 2026 |
No analyst notes on BIIB yet.
Analyst Ratings
32 analysts covering
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Consensus |
|---|---|---|---|---|---|---|
| Current | 4 | 20 | 11 | 1 | 0 | Buy2.25 |
| 1 mo ago | 3 | 19 | 12 | 1 | 0 | Buy2.31 |
| 2 mo ago | 3 | 20 | 11 | 1 | 0 | Buy2.29 |
| 3 mo ago | 3 | 20 | 12 | 1 | 0 | Buy2.31 |
Members whose judged calls on BIIB have played out most reliably.
No settled calls on BIIB yet. Nobody has filed a call with a deadline on it.
A member is listed once they have three judged calls on a name.
A call with a target is judged on whether the price reaches it by the deadline, counting each day's high (a buy) or low (a sell) from the day after the call was made. A call without one is judged on whether the price at the close on the deadline is higher (a buy) or lower (a sell) than the price the call was made at: the live price when it was saved, for a call made with Make a call, or the last close before the day it was filed, for a call made in a note. Not against the market or an index.
A percentage appears once five calls have reached their deadline. A target reached sooner is shown as played out early, and counts toward the percentage when its deadline passes, because a miss cannot be known before then.
A member’s prediction, judged on price history · not investment advice